A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional
40 weeks in patients with PTSD who have participated in a double-blind lead-in study and
completed an initial 12-week open-label extension study (TNX-CY-P303).